Home Newsfeeds EF Hutton Reiterates Buy on Glimpse Group, Maintains $7 Price Target

EF Hutton Reiterates Buy on Glimpse Group, Maintains $7 Price Target

EF Hutton analyst Michael Albanese reiterates Glimpse Group (NASDAQ:VRAR) with a Buy and maintains $7 price target.

byBenzinga Newsdesk

February 16, 2023

1 minute read

EF Hutton analyst Michael Albanese reiterates Glimpse Group (NASDAQ:VRAR) with a Buy and maintains $7 price target.

Legal
News

GeoVax Receives Notice Of Allowance For U.S. Patent Titled ‘METHOD OF GENERATING A ZIKV IMMUNE RESPONSE UTILIZING A RECOMBINANT MODIFIED VACCINIA ANKARA VECTOR ENCODING THE NS1 PROTEIN’

By Benzinga Newsdesk

December 16, 12:31 PM

https://patentcenter.uspto.gov/#!/applications/17000768/ifw/docs

GOVX

Strong Momentum In Homebuilding Industry: Raymond James’ Take On Upgraded Ratings And Increased Price Targets

By Lekha Gupta

July 14, 12:17 PM

Raymond James analyst Buck Horne raised the rating on several homebuilding stocks, given his bullish stance on homebuilding industry growth.

KBH

Stone Presents Plans For More Than Doubling Profitability Over The Next 4 Years, Hoping To Exceed An Adjusted Net Income Of R$4.3B; In 2027, Plans To Exceed R$600B In TPV And A Take Rate Above 2.70% In MSMB, Exceed R$14B In Client Deposits, And Achieve…

By Benzinga Newsdesk

November 15, 4:30 PM

The announcement was made during the Investor Day held in New York, for presenting the company's medium- and long-term plans

STNE

FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless – Stocks To Watch

By Vandana Singh

September 12, 4:06 PM

According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for relief from

BAYRY

EF Hutton Reiterates Buy on Glimpse Group, Maintains $7 Price Target

Related Posts

GeoVax Receives Notice Of Allowance For U.S. Patent Titled ‘METHOD OF GENERATING A ZIKV IMMUNE RESPONSE UTILIZING A RECOMBINANT MODIFIED VACCINIA ANKARA VECTOR ENCODING THE NS1 PROTEIN’

Strong Momentum In Homebuilding Industry: Raymond James’ Take On Upgraded Ratings And Increased Price Targets

Stone Presents Plans For More Than Doubling Profitability Over The Next 4 Years, Hoping To Exceed An Adjusted Net Income Of R$4.3B; In 2027, Plans To Exceed R$600B In TPV And A Take Rate Above 2.70% In MSMB, Exceed R$14B In Client Deposits, And Achieve…

FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless – Stocks To Watch